Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

819.03 +6.60 (+0.81%)
Streaming Delayed Price Updated: 9:43 AM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy
Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly. 
Via Benzinga
5 Monster Stocks to Hold for the Next 10 Years
Via The Motley Fool
Topics Artificial Intelligence Economy
1 Stock Down 34% This Year to Buy and Hold
Via The Motley Fool
Billionaire Stanley Druckenmiller Has Unloaded Shares of Last Year's 2 Top Performing AI Stocks and Is Piling Into a Growth Stock That Has Climbed 150% in 3 Years
Via The Motley Fool
Topics Artificial Intelligence Stocks
1 Underrated Reason to Buy This Market-Beating Stock
Via The Motley Fool
Prediction: Eli Lilly Will Reach a $1 Trillion Valuation by 2027
Via The Motley Fool
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin? 
Via MarketBeat
The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.
Amgen is hoping to take on Eli Lilly and Novo Nordisk with a potential monthly shot, MariTide. 
Via Investor's Business Daily
Novo Nordisk Stock: Is It Still a Smart Buy?
Via The Motley Fool
Time to Buy These 3 Cheap Stocks?
Via The Motley Fool
Should You Invest $1,000 in Eli Lilly today?
Via The Motley Fool
Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologics
China's drug regulator accepted the companies’ NDA for a combination therapy targeting advanced renal cell carcinoma. 
Via Stocktwits
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38. 
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
The 9 Best Stocks to Buy Now in June (2025)
Via The Motley Fool
Topics Artificial Intelligence
Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal
Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies targeting metabolic diseases. 
Via Benzinga
Better Dividend ETF to Buy Now: Schwab U.S. Dividend Equity ETF or Vanguard Dividend Appreciation ETF?
Dive deep into two popular dividend ETFs to determine which is right for your portfolio. 
Via The Motley Fool
Topics ETFs Stocks
IBD 50's Hims & Hers Health Shoots Higher On A Key Takeover In Europe
The company hopes the deal will help it snag business in the UK, building a similar model to its U.S. platform. 
Via Investor's Business Daily
Topics ETFs
Looking For Summer Seasonal Gains? Here Are 10 S&P 500 Stocks That Historically Rallied In June
Seasonal trends highlight 10 S&P 500 stocks with strong June performance. Tesla leads the list, joined by consistent gainers like Eli Lilly. 
Via Benzinga
Topics Stocks
Eli Lilly Rises 1.5% After Key Trading Signal
A significant trading signal occurred for Eli Lilly stock, as it demonstrated a power inflow at $734.98, after which LLY rose up to 1.5%. 
Via Benzinga
Could Viking Therapeutics Become the Next Eli Lilly?
Via The Motley Fool
Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia
 
Via PR Leap
Top S&P500 movers in Friday's session
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival. 
Via Investor's Business Daily
Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure
Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study. 
Via Investor's Business Daily
2 Top Stocks to Buy With Less Than $100
Via The Motley Fool
3 American Growth Giants to Invest in for the Long Haul
Via The Motley Fool
Topics Artificial Intelligence World Trade
2 Beaten-Down Stocks to Buy on the Dip
Via The Motley Fool
Looking for a Blend of Growth and Dividend Stocks Amid Market Uncertainty? Consider This Low-Cost Vanguard ETF.
Via The Motley Fool
Topics Artificial Intelligence ETFs
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position? 
Via Investor's Business Daily
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.